Anti-competence effects of synthetic phthalide derivatives on platelet-derived growth factor-induced DNA synthesis in primary cultures of rat aorta smooth muscle cells.
The inhibitory effect of 3-butylidene-4,5-dihydroxyphthalide (BP-42) on platelet derived growth factor (PDGF)-BB-induced DNA synthesis was investigated in synchronized smooth muscle cells (SMC) in primary culture of rat aorta. BP-42 (0.3-3 micrograms/ml) inhibited the PDGF-BB (30 ng/ml)-stimulated [3H]thymidine incorporation of the SMC in a concentration-dependent manner. BP-42 inhibited both the competence and progression phases of [3H]thymidine incorporation induced by PDGF-BB. Using the competence assay, BP-42 (0.3-10 micrograms/ml) delayed PDGF-BB (30 ng/ml)-accelerated starting time of [3H]thymidine incorporation in a concentration-dependent manner, confirming that BP-42 inhibited PDGF-BB-induced competence phase of DNA synthesis of SMC. BP-42 (1-10 micrograms/ml) also delayed basic fibroblast growth factor (bFGF: 30 ng/ml)-accelerated starting time of [3H]thymidine incorporation. The inhibitory potency of BP-42 for the competence action of PDGF-BB was similar to that for the action of bFGF. BP-421 (3-heptylidene-4,5-dihydroxyphthalide) and BP-422 (3-benzylidene-4,5-dihydroxyphthalide) had 3-fold greater inhibitory potencies than BP-42 for the PDGF-BB-induced competence activity. These results demonstrated that BP-42 inhibited PDGF-BB-induced competence activity of DNA synthesis in primary cultured SMC of rat aorta via a common signal transduction mechanism with bFGF. BP-421 and BP-422 were more potent inhibitors for the competence activity, suggesting that they may become a prototype of new anti-atherosclerotic drugs.
Mimura
Y
Y
Department of Hospital Pharmacy, Toyama Medical and Pharmaceutical University, Japan.
Kobayashi
S
S
Okabe
M
M
Kimura
I
I
Horikoshi
I
I
Kimura
M
M
D000818:Animals; D001011:Aorta / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis*; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D010796:Phthalic Anhydrides / Q000494:pharmacology*; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
C098817:3-butylidene-4,5-dihydroxyphthalide; D010796:Phthalic Anhydrides; D010982:Platelet-Derived Growth Factor; D016222:Fibroblast Growth Factor 2; D004247:DNA